Atherogenic effects of Chlamydia pneumoniae: Refuting the innocent bystander hypothesis

Journal of Thoracic and Cardiovascular Surgery

Volumn 126, Issue 3, 2003, Pages 688-693

  Selzman, Craig H ^a,d   Netea, Mihai G ^c   Zimmerman, Michael A ^b   Weinberg, Adriana ^c   Reznikov, Leonid L ^c   Grover, Frederick L ^b   Dinarello, Charles A ^c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CELL CYCLE PROTEIN; CYCLINE; CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 8; MACROLIDE; PROTEIN P53;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BYSTANDER EFFECT; CELL COUNT; CELL PROLIFERATION; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; VASCULAR SMOOTH MUSCLE;

EID: 0141853937     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5223(03)00738-4     Document Type: Article

References (24)

1. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2:983-6.
2. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997;350:430-6.
3. Meier CR, Derby LE, Jick SS, Vasilakis C, Hick H. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA. 1999; 281:427-31.
4. Muhlestein JB, Anderson JL, Hammond EH, Zhao L, Trehan S, Schwobe EP, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 1998;97:633-6.
5. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404-7.
6. Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn TC. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cell. Infect Immun. 1996;64:1614-20.
7. Selzman CH, Miller SA, Harken AH. Therapeutic implications of inflammation in atherosclerotic cardiovascular disease. Ann Thorac Surg. 2001;71:2066-74.
8. Roblin PM, Dumornay W, Hammerschlag MR. Use of Hep-2 cells for improved isolation and passage of Chlamydia pneumoniae. J Clin Microbiol. 1992;30:1968-71.
9. Selzman CH, McIntyre RC, Shames BD, Whitehill TA, Banerjee A, Harken AH. Interleukin-10 inhibits human vascular smooth muscle proliferation. J Mol Cell Cardiol. 1998;30:889-96.
10. Selzman CH, Shames BD, Reznikov LL, Miller SA, Meng X, Barton H, et al. Liposomal delivery of purified inhibitory-kappaBalpha inhibits tumor necrosis factor-alpha-induced human vascular smooth muscle proliferation. Circ Res. 1999;84:867-75.
11. Puren AJ, Fantuzzi G, Gu Y, Su M, Dinarello CA. Interteukin-18 (IFN-inducing factor) induces IL-8 and IL-1 via TNF production from non-CD 14+ human blood mononuclear cells. J Clin Invest. 1998;101: 711-21.
12. Knoebel E, Vijayagopal P, Figueroa JE. Martin DH. In vitro infection of smooth muscle cells by Chlamydia pneumoniae. Infect Immun. 1997;65:503-6.
13. Laurila A, Bloigu A, Nayha S, Hassi J, Leinonen M, Saikku P. Chronic Chlamydia pneumoniae infection in associated with a serum lipid profile known to be a risk factor for atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:2910-3.
14. Coombes BK, Mahony JB. Chlamydia pneumoniae infection of human endothelial cells induces proliferation of smooth muscle cells via an endothelial cell-derived soluble factor(s). Infect Immun. 1999;67:2909-15.
15. Kuakoranta-Tolvanen SS, Teppo AM, Laitinen K, Saikku P, Linnavuori K, Leinonen M. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb Pathog. 1996;21:215-21.
16. Netea MG, Selzman CH, Kullberg BJ, Gallam JMD, Weinberg A, Stalenhoef AFH, et al. Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells. Eur J Immunol. 2000;30:541-9.
17. Selzman CH, Shames BD, Whitehill TA, Harken AH, Mcintyre RC Jr. Class II cytokine receptor ligands inhibit human vascular smooth muscle proliferation. Surgery. 1998;124:318-27.
18. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR. The p53 network. J Biol Chem. 1998;273:1-4.
19. Miller SA, Selzman CH, Shames BD, Barton HA, Johnson SM, Harken AH. Chlamydia pneumoniae activates NF-κB and AP-1 in human vascular smooth muscle and induces cellular proliferation. J Surg Res. 2000;90:76-81.
20. Dechend R, Maass M, Gieffers J, Dietz R, Scheidereit C, Leutz A, et al. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI- 1 expression: a potential link to accelerated arteriosclerosis. Circulation. 1999;100:1369-73.
21. Selzman CH, Shames BD, McIntyre RC Jr, Banerjee A, Harken AH. The NFκB inhibitory peptide, IκBα, prevents human vascular smooth muscle proliferation. Ann Thorac Surg. 1999;67:1227-32.
22. Yue TL, Wang X, Sung CP, Olson B, McKenna PJ, Gu JL, et al. Interleukin 8: a mitogen and chemoattractant for vascular smooth muscle cells. Circ Res. 1994;75:1-7.
23. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet. 1997;350:404-7.
24. Muhlestein JB, Anderson JL, Carlquist JF, Salunkhe K, Home BD, Pearson RR, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation. 2000;12:1755-60.